Advertisment
Nuvectis Pharma will present clinical and preclinical findings for NXP900 at AACR-NCI-EORTC 2025
Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.
| Titles and Presenters | Presentation Details |
| Title Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900 Presenter |
Session Poster Session A Poster Number Session Date / Time |
| Title NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, potently inhibits tumor growth in FAT1 mutated xenograft models Presenter |
Session Poster Session A Poster Number Session Date / Time |
